Why
Avoid
1. Seeking Rich Valuation
2. Limited Products
3. Top 10 Customers Account for Majority Revenue
4. Increase in Product Prices Boosts Revenue
5. Potential Conflict of Interest
6. High Attrition Rate
This analysis takes into account the company's future rather than listing gains. It is also not based on our big data analysis.
Issue Details
| Issue Opens | 9th November 2022 |
| Issue Closes | 11th November 2022 |
| Price Band | Rs. 386-407 |
| Issue size (Upper Band) | 1462 Crs |
| Issue Type | Fresh Issue & OFS |
| Market cap (based on upper band) | 5010 Crs |
| Sales-March 2022 | 1130.4 Crs |
| Net Profit-March 2022 | 188.6 Crs |
| Industry | Chemicals |
| Promoters | Chemikas Speciality LLP |
| Lead Manager | IIFL Securities Ltd |
The Offer comprises a Fresh Issue as well as an Offer for Sale by the Selling Shareholders for partial or full redemption of NCDs issued by the Company.
| NAME | TYPE | No of shares offered | % of total offering |
|---|---|---|---|
| Chemikas Speciality LLP | Promoter | 20,00,000 | 12% |
| India Resurgence Fund, Scheme I | Institutional Investor | 38,35,562 | 24% |
| India Resurgence Fund, Scheme II | Institutional Investor | 64,78,876 | 40% |
| Piramal Natural Resources Private Limited | Institutional Investor | 38,35,562 | 24% |
The company is into marine chemicals major, focusing on products like bromine, Industrial salt and sulphate of potash. Their manufacturing unit is in Hajipur, Gujarat.
About 70% of the revenue came from exports in FY22.
Pharmaceuticals & Agrochemicals, Energy storage, fertilizers are some of the sectors this company serves to.
They are a major exporter of bromine and Industrial salts which account for 99% of the revenue while only 1% of the revenue came from sulphate of potash in FY22.
| Segment Revenue Breakup by product | |||
|---|---|---|---|
| (%) | FY22 | FY21 | FY20 |
| Bromine | 53.6 | 46.5 | 35.4 |
| Industrial Salts | 45.4 | 49.1 | 57.9 |
| Sulphate of potash | 1.0 | 4.4 | 6.6 |
| Segment Revenue Breakup by geography | |||
|---|---|---|---|
| (%) | FY22 | FY21 | FY20 |
| India | 29.7 | 25.6 | 21.6 |
| Rest of the world | 70.3 | 74.4 | 78.4 |
The company provided financials for three years beginning in March 2020, which is not a good year to start because of the Covid impact. They should have provided five-year financials to better understand the company's growth.
In FY22, it clocked a revenue of over 1100 crores and a net profit of 189 crores.
It reported sales of Rs 400 crore for the quarter ended June 2022, up from Rs 201 crore in the corresponding quarter last year.
Its net profit increased to Rs 84 crore from Rs 19 crore during the same period last year. The rise in net profit was primarily due to an increase in chemical prices.
| Qtr | Qtr | Annual | Annual | Annual | |
|---|---|---|---|---|---|
| Jun-22 | Jun-21 | Mar-22 | Mar-21 | Mar-20 | |
| Sales | 400 | 201 | 1130 | 741 | 608 |
| Net Profit | 84 | 19 | 189 | 67 | -36 |